What Powered IDEXX Laboratories (NASDAQ:IDXX) to a 22% Jump on 10% Revenue Growth?

Vinay Lochav

05 November 2026 12:48 AM AEDT

What Powered IDEXX Laboratories (NASDAQ:IDXX) to a 22% Jump on 10% Revenue Growth?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

IDEXX Laboratories (NASDAQ:IDXX) rose about 22% on November 2, 2026, closing near USD 671.64 after third-quarter results.
Third-quarter Revenue reached USD 1.214 billion, up 10%, against about USD 1.19 billion expected, with diluted Earnings of USD 4.01 a share against USD 3.40.
New 2026 earnings guidance is USD 14.96 to USD 15.16, up from USD 14.69 to USD 14.94, with revenue guided to USD 4.741 billion to USD 4.767 billion.
The Operating Margin came in at 33.1%, up from 32.1%, while the full-year margin range of 32.1% to 32.3% sits below the 32.3% to 32.5% given in August.

What IDEXX Reported

IDEXX reported third-quarter 2026 results on November 2, 2026. Revenue rose 10% to about USD 1.214 billion, and diluted earnings climbed 18% to USD 4.01 a share, above the published consensus of USD 3.71. Operating margin was 33.1%. Recurring diagnostics revenue in its companion animal group was USD 967 million, up 11%, led by a 14% rise in consumables for its in-clinic analysers. The company placed 5,780 premium instruments, including 1,904 of its inVue Dx analysers. The shares closed up about 22% at USD 671.64, one of the largest gains in the S&P 500 that day, according to published market data. Recurring diagnostics growth is the figure investors prize most because it repeats each quarter, and premium instrument placements feed it. Organic revenue growth guidance was lifted to 9.3% to 10.0% from 8.5% to 9.7%, a sign the beat was not only currency.

What Is Inside the Guidance

IDEXX raised its 2026 outlook for revenue to USD 4.741 billion to USD 4.767 billion, organic growth to 9.3% to 10.0% and earnings to USD 14.96 to USD 15.16. The operating margin range of 32.1% to 32.3% is lower than the 32.3% to 32.5% given in the second quarter, so the earnings raise came from items below operating profit, such as tax and interest. One analysis attributes the raise to a lower tax rate, lower interest expense and fewer shares, and links the margin cut to costs from its CoVet software deal. The Business follows a razor-and-blade model: each analyser placed generates years of consumable sales. Earnings guidance rose by about USD 0.25 at the low end and USD 0.22 at the high end, simple arithmetic, so IDEXX Laboratories (NASDAQ:IDXX) has narrowed its outlook while lifting it.

Risks and What to Watch Next

The same analysis notes that same-store clinical visits fell 1.8% and rapid assay testing volumes declined, with price alone keeping those sales growing. If veterinary visits stay soft, Volume growth could slow. Margin guidance implies little improvement in the fourth quarter. After a 22% one-day rise, expectations are high, and moves of that size can reverse. Investors will watch visit trends, instrument placements, consumable growth, the cost of software integration and whether margins hold in the fourth quarter. A seventh straight quarterly earnings beat, noted in published coverage, also sets a high bar, since a miss after a long run of beats tends to be punished.

Where Things Stand

IDEXX jumped about 22% because it beat on revenue and earnings, raised revenue and earnings guidance and showed Recurring Revenue growth of 11%. Not all of the gain is operational: the earnings raise leans on tax, interest and share count, and the margin outlook was lowered. For IDEXX Laboratories (NASDAQ:IDXX), visit trends and fourth-quarter margins are the next tests. A 22% day can partly reverse. Nothing here is Investment advice or a price forecast.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.